CoChat
Sign Up
Cited by 90Cancer Mechanisms and TherapyComputational Drug Discovery MethodsCancer therapeutics and mechanisms

New drugs are not enough‑drug repositioning in oncology: An update

Open access
Armando, Romina, Mengual G�mez, Diego, Gomez, Daniel·2020·International Journal of Oncology
DOI 10.3892/ijo.2020.4966PMC PMC7010222
Open this paper in CoChat — free accountOpen PDF

Abstract

Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that are already known for use treating other diseases. The advantages of this are that several important drug characteristics are already established (including efficacy, pharmacokinetics, pharmacodynamics and toxicity), making the process of research for a putative drug quicker and less costly. Drug repositioning in oncology has received extensive focus. The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ijo.2020.4966

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mebendazole suppresses tumor growth in various cancer cell lines and animal models through inhibition of microtubule polymerization.

    “MBZ has been shown to potentially suppress tumor growth in various cancer cell lines and animal models through the inhibition of microtubule polymerization”

    From Drug repurposing for cancer therapy (2024) · cites this paper as [158]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 544

  1. [1]Gupta SC Sung B Prasad S Webb LJ Aggarwal BB Cancer drug discovery by repurposing: Teaching new tricks to old dogs Trends Pharmacol Sci 34 508 517 2013 10.1016/j.tips.2013.06.005 23928289 · DOI
  2. [2]Hanusova V Skalova L Kralova V Matouskova P Potential anti-cancer drugs commonly used for other indications Curr Cancer Drug Targets 15 35 52 2015 10.2174/1568009615666141229152812 25544649 · DOI
  3. [3]Paul SM Mytelka DS Dunwiddie CT Persinger CC Munos BH Lindborg SR Schacht AL How to improve R&D productivity: The pharmaceutical industry's grand challenge Nat Rev Drug Discov 9 203 214 2010 10.1038/nrd3078 20168317 · DOI · Paper page
  4. [4]Adams CP Brantner VV Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff (Millwood) 25 420 428 2006 10.1377/hlthaff.25.2.420 16522582 · DOI
  5. [5]Nowak-Sliwinska P Scapozza L Ruiz IAA Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer Biochim Biophys Acta Rev Cancer 1871 434 454 2019 10.1016/j.bbcan.2019.04.005 31034926 PMC6528778 · DOI
  6. [6]Bertolini F Sukhatme VP Bouche G Drug repurposing in oncology-patient and health systems opportunities Nat Rev Clin Oncol 12 732 742 2015 10.1038/nrclinonc.2015.169 26483297 · DOI
  7. [7]Chong CR Sullivan DJ Jr New uses for old drugs Nature 448 645 646 2007 10.1038/448645a 17687303 · DOI
  8. [8]Ashburn TT Thor KB Drug repositioning: Identifying and developing new uses for existing drugs Nat Rev Drug Discov 3 673 683 2004 10.1038/nrd1468 15286734 · DOI · Paper page
  9. [9]Shim JS Liu JO Recent advances in drug repositioning for the discovery of new anticancer drugs Int J Biol Sci 10 654 663 2014 10.7150/ijbs.9224 25013375 PMC4081601 · DOI · Paper page
  10. [10]Pantziarka P Verbaanderd C Sukhatme V Rica Capistrano I Crispino S Gyawali B Rooman I Van Nuffel AM Meheus L Sukhatme VP Bouche G ReDO_DB: The repurposing drugs in oncology database Ecancermedicalscience 12 886 2018 10.3332/ecancer.2018.886 30679953 PMC6345075 · DOI
  11. [11]Xue H Li J Xie H Wang Y Review of drug repositioning approaches and resources Int J Biol Sci 14 1232 1244 2018 10.7150/ijbs.24612 30123072 PMC6097480 · DOI
  12. [13]Woodrow CJ Haynes RK Krishna S Artemisinins Postgrad Med J 81 71 78 2005 10.1136/pgmj.2004.028399 15701735 PMC1743191 · DOI
  13. [14]White NJ Anaemia and malaria Malar J 17 371 2018 10.1186/s12936-018-2509-9 30340592 PMC6194647 · DOI
  14. [15]Gunjan S Sharma T Yadav K Chauhan BS Singh SK Siddiqi MI Tripathi R Artemisinin derivatives and synthetic trioxane trigger apoptotic cell death in asexual stages of plasmodium Front Cell Infect Microbiol 8 256 2018 10.3389/fcimb.2018.00256 30094226 PMC6070741 · DOI
  15. [16]Jeong DE Song HJ Lim S Lee SJ Lim JE Nam DH Joo KM Jeong BC Jeon SS Choi HY Lee HW Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis Oncotarget 6 33046 33064 2015 10.18632/oncotarget.5422 26426994 PMC4741748 · DOI
  16. [17]Slezakova S Ruda-Kucerova J Anticancer activity of artemisinin and its derivatives Anticancer Res 37 5995 6003 2017 29061778
  17. [18]Jiang F Zhou JY Zhang D Liu MH Chen YG Artesunate induces apoptosis and autophagy in HCT116 colon cancer cells, and autophagy inhibition enhances the artesunate-induced apop-tosis Int J Mol Med 42 1295 1304 2018 29901098 PMC6089754
  18. [19]Dell'Eva R Pfeffer U Vené R Anfosso L Forlani A Albini A Efferth T Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesu-nate Biochem Pharmacol 68 2359 2366 2004 10.1016/j.bcp.2004.08.021 15548382 · DOI
  19. [20]Zheng L Pan J The Anti-malarial drug artesunate blocks Wnt/β-catenin pathway and inhibits growth, migration and invasion of uveal melanoma cells Curr Cancer Drug Targets 18 988 998 2018 10.2174/1568009618666180425142653 29692251 · DOI
  20. [21]Patyar S Patyar RR Medhi B Khanduja KL Chemopreventive effect of artesunate in 1,2-dimethylhydrazine-induced rat colon carcinogenesis J Adv Pharm Technol Res 8 102 107 2017 28795024 PMC5527695
  21. [22]von Hagens C Walter-Sack I Goeckenjan M Storch-Hagenlocher B Sertel S Elsässer M Remppis BA Munzinger J Edler L Efferth T Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2) Phytomedicine 54 140 148 2019 10.1016/j.phymed.2018.09.178 30668363 · DOI
  22. [23]Chen X Zhang XL Zhang GH Gao YF Artesunate promotes Th1 differentiation from CD4+ T cells to enhance cell apoptosis in ovarian cancer via miR-142 Braz J Med Biol Res 52 e7992 2019 10.1590/1414-431x20197992 31038546 PMC6489539 · DOI
  23. [24]Wang Z Wang C Wu Z Xue J Shen B Zuo W Wang Z Wang SL Artesunate suppresses the growth of prostatic cancer cells through inhibiting androgen receptor Biol Pharm Bull 40 479 485 2017 10.1248/bpb.b16-00908 28381803 · DOI
  24. [25]Chauhan AK Min KJ Kwon TK RIP1-dependent reactive oxygen species production executes artesunate-induced cell death in renal carcinoma Caki cells Mol Cell Biochem 435 15 24 2017 10.1007/s11010-017-3052-7 28466458 · DOI
  25. [26]Tong Y Liu Y Zheng H Zheng L Liu W Wu J Ou R Zhang G Li F Hu M Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling Oncotarget 7 31413 31428 2016 10.18632/oncotarget.8920 27119499 PMC5058767 · DOI
  26. [27]Beccafico S Morozzi G Marchetti MC Riccardi C Sidoni A Donato R Sorci G Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells Carcinogenesis 36 1071 1083 2015 10.1093/carcin/bgv098 26153023 · DOI
  27. [28]Crespo-Ortiz MP Wei MQ Antitumor activity of artemisinin and its derivatives: From a well-known antimalarial agent to a potential anticancer drug J Biomed Biotechnol 2012 247597 2012 10.1155/2012/247597 22174561 PMC3228295 · DOI
  28. [29]Xia X Fan X Zhao M Zhu P The relationship between ferroptosis and tumors: A novel landscape for therapeutic approach Curr Gene Ther 19 117 124 2019 10.2174/1566523219666190628152137 31264548 PMC7046989 · DOI
  29. [30]Li Z Li Q Wu J Wang M Yu J Artemisinin and its derivatives as a repurposing anticancer agent: What Else Do We Need to Do? Molecules 21 pii: E1331 2016 PMC6272993 27739410
  30. [31]Zhou Y Li W Xiao Y Profiling of multiple targets of arte-misinin activated by hemin in cancer cell proteome ACS Chem Biol 11 882 888 2016 10.1021/acschembio.5b01043 26854499 · DOI
  31. [33]Aletaha D Neogi T Silman AJ Funovits J Felson DT Bingham CO III Birnbaum NS Burmester GR Bykerk VP Cohen MD 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative Arthritis Rheum 62 2569 2581 2010 10.1002/art.27584 20872595 · DOI
  32. [34]Wu B Yang X Yan M Synthesis and Structure-activity relationship study of antimicrobial auranofin against ESKAPE pathogens J Med Chem 62 7751 7768 2019 10.1021/acs.jmedchem.9b00550 31386365 PMC7941214 · DOI
  33. [35]Emery P Suarez-Almazor M Rheumatoid arthritis Clin Evid: 1349 1371 2003 15366179
  34. [36]Roder C Thomson MJ Auranofin: Repurposing an old drug for a golden new age Drugs R D 15 13 20 2015 10.1007/s40268-015-0083-y 25698589 PMC4359176 · DOI
  35. [37]Perez MVR Roife D Dai B Pratt M Dobrowolski R Kang Y Li X Augustine JJ Zielinski R Priebe W Fleming JB Antineoplastic effects of auranofin in human pancreatic adeno-carcinoma preclinical models Surgery Open Science 1 56 63 2019 10.1016/j.sopen.2019.05.004 PMC8083010 33981979 · DOI
  36. [38]Pessetto ZY Weir SJ Sethi G Broward MA Godwin AK Drug repurposing for gastrointestinal stromal tumor Mol Cancer Ther 12 1299 1309 2013 10.1158/1535-7163.MCT-12-0968 23657945 PMC3707936 · DOI
  37. [39]Li H Hu J Wu S Wang L Cao X Zhang X Dai B Cao M Shao R Zhang R Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells Oncotarget 7 3548 3558 2016 26657290 PMC4823126
  38. [40]Xiaobo C Majidi M Feng M Shao R Wang J Zhao Y Baladandayuthapani V Song J Fang B Ji L TUSC2(FUS1)-erlotinib induced vulnerabilities in epidermal growth factor Receptor(EGFR) wildtype non-small cell lung cancer(NSCLC) targeted by the repurposed drug auranofin Sci Rep 6 35741 2016 10.1038/srep35741 27845352 PMC5109231 · DOI
  39. [41]Mellemkjaer L Linet MS Gridley G Frisch M Møller H Olsen JH Rheumatoid arthritis and cancer risk Eur J Cancer 32A 1753 1757 1996 10.1016/0959-8049(96)00210-9 8983286 · DOI
  40. [42]Porta C Paglino C Mosca A Targeting PI3K/Akt/mTOR signaling in cancer Front Oncol 4 64 2014 10.3389/fonc.2014.00064 24782981 PMC3995050 · DOI
  41. [43]Nitulescu GM Van De Venter M Nitulescu G Ungurianu A Juzenas P Peng Q Olaru OT Grădinaru D Tsatsakis A Tsoukalas D The Akt pathway in oncology therapy and beyond (Review) Int J Oncol 53 2319 2331 2018 30334567 PMC6203150
  42. [44]El Rashedy AA Aboul-Enein HY Benzimidazole derivatives as potential anticancer agents Mini Rev Med Chem 13 399 407 2013 23190032
  43. [45]Tahlan S Kumar S Kakkar S Narasimhan B Benzimidazole scaffolds as promising antiproliferative agents: A review BMC Chem 13 66 2019 10.1186/s13065-019-0579-6 31384813 PMC6661752 · DOI
  44. [46]Herd RP Miller TB Gabel AA A field evaluation of pro-benzimidazole, benzimidazole, and non-benzimidazole anthelmintics in horses J Am Vet Med Assoc 179 686 691 1981 7341582
  45. [47]Bansal Y Kaur M Bansal G Antimicrobial potential of benzimidazole derived molecules Mini Rev Med Chem 19 624 646 2019 10.2174/1389557517666171101104024 29090668 · DOI
  46. [48]Králová V Hanušová V Staňková P Knoppová K Čáňová K Skálová L Antiproliferative effect of benzimidazole anthelmin-tics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines Anticancer Drugs 24 911 919 2013 10.1097/CAD.0b013e3283648c69 23884106 · DOI
  47. [50]Pourgholami MH Woon L Almajd R Akhter J Bowery P Morris DL In vitro and in vivo suppression of growth of hepato-cellular carcinoma cells by albendazole Cancer Lett 165 43 49 2001 10.1016/S0304-3835(01)00382-2 11248417 · DOI · Paper page
  48. [51]Khalilzadeh A Wangoo KT Morris DL Pourgholami MH Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways Biochem Pharmacol 74 407 414 2007 10.1016/j.bcp.2007.05.006 17560963 · DOI
  49. [52]Chu SW Badar S Morris DL Pourgholami MH Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole Anticancer Res 29 3791 3796 2009 19846910
  50. [53]Teruel M Dercole J Catalano R Evaluation of potential embryo toxicity of albendazole sulphoxide in CF1 mice Biocell 35 29 33 2011 21667669
  51. [54]Pourgholami MH Yan Cai Z Lu Y Wang L Morris DL Albendazole: A potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice Clin Cancer Res 12 1928 1935 2006 10.1158/1078-0432.CCR-05-1181 16551879 · DOI · Paper page
  52. [55]Wagil M Bialk-Bielinska A Puckowski A Wychodnik K Maszkowska J Mulkiewicz E Kumirska J Stepnowski P Stolte S Toxicity of anthelmintic drugs (fenbendazole and flubendazole) to aquatic organisms Environ Sci Pollut Res Int 22 2566 2573 2015 10.1007/s11356-014-3497-0 25189803 PMC4315879 · DOI
  53. [56]Canova K Rozkydalova L Rudolf E Anthelmintic flubendazole and its potential use in anticancer therapy Acta Medica (Hradec Kralove) 60 5 11 2017 10.14712/18059694.2017.44 28399389 · DOI
  54. [57]Hou ZJ Luo X Zhang W Peng F Cui B Wu SJ Zheng FM Xu J Xu LZ Long ZJ Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells Oncotarget 6 6326 6340 2015 10.18632/oncotarget.3436 25811972 PMC4467440 · DOI
  55. [58]Spagnuolo PA Hu J Hurren R Wang X Gronda M Sukhai MA Di Meo A Boss J Ashali I Beheshti Zavareh R The anti-helmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma Blood 115 4824 4833 2010 10.1182/blood-2009-09-243055 20348394 · DOI
  56. [59]Michaelis M Agha B Rothweiler F Löschmann N Voges Y Mittelbronn M Starzetz T Harter PN Abhari BA Fulda S Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen Sci Rep 5 8202 2015 10.1038/srep08202 25644037 PMC4314641 · DOI
  57. [60]Canova K Rozkydalova L Vokurkova D Rudolf E Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells Toxicol In Vitro 46 313 322 2018 10.1016/j.tiv.2017.10.025 29107018 · DOI
  58. [61]Bai RY Staedtke V Aprhys CM Gallia GL Riggins GJ Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme Neuro Oncol 13 974 982 2011 10.1093/neuonc/nor077 21764822 PMC3158014 · DOI · Paper page
  59. [62]Mukhopadhyay T Sasaki J Ramesh R Roth JA Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo Clin Cancer Res 8 2963 2969 2002 12231542
  60. [63]Sasaki J Ramesh R Chada S Gomyo Y Roth JA Mukhopadhyay T The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells Mol Cancer Ther 1 1201 1209 2002 12479701
  61. [64]Nygren P Fryknas M Agerup B Larsson R Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer J Cancer Res Clin Oncol 139 2133 2140 2013 10.1007/s00432-013-1539-5 24135855 PMC3825534 · DOI · Paper page
  62. [65]Doudican NA Byron SA Pollock PM Orlow SJ XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts Anticancer Drugs 24 181 188 2013 10.1097/CAD.0b013e32835a43f1 23059386 · DOI
  63. [67]Jin UH Kim SB Safe S Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway Chem Res Toxicol 28 907 918 2015 10.1021/tx5005198 25826687 PMC4948974 · DOI
  64. [68]Zhang JL Liu M Yang Q Lin SY Shan HB Wang HY Xu GL Effects of omeprazole in improving concurrent chemo-radiotherapy efficacy in rectal cancer World J Gastroenterol 23 2575 2584 2017 10.3748/wjg.v23.i14.2575 28465642 PMC5394521 · DOI
  65. [69]Fako VE Wu X Pflug B Liu JY Zhang JT Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase J Med Chem 58 778 784 2015 10.1021/jm501543u 25513712 PMC4306520 · DOI
  66. [70]Haladyj E Sikora M Felis-Giemza A Olesinska M Antimalarialsare they effective and safe in rheumatic diseases? Reumatologia 56 164 173 2018 10.5114/reum.2018.76904 30042604 PMC6052376 · DOI
  67. [72]Bondeson J Sundler R Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: Implications for their mode of action in rheumatoid arthritis Gen Pharmacol 30 357 366 1998 10.1016/S0306-3623(97)00269-3 9510087 · DOI
  68. [73]Chou AC Fitch CD Heme polymerase: Modulation by chloroquine treatment of a rodent malaria Life Sci 51 2073 2078 1992 10.1016/0024-3205(92)90158-L 1474861 · DOI
  69. [74]Untaroiu AM Carey MA Guler JL Papin JA Leveraging the effects of chloroquine on resistant malaria parasites for combination therapies BMC Bioinformatics 20 186 2019 10.1186/s12859-019-2756-y 30987583 PMC6466727 · DOI
  70. [75]Verbaanderd C Maes H Schaaf MB Sukhatme VP Pantziarka P Sukhatme V Agostinis P Bouche G Repurposing drugs in oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents Ecancermedicalscience 11 781 2017 10.3332/ecancer.2017.781 29225688 PMC5718030 · DOI
  71. [76]Mulcahy Levy JM Zahedi S Griesinger AM Morin A Davies KD Aisner DL Kleinschmidt-DeMasters BK Fitzwalter BE Goodall ML Thorburn J Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors Elife 6 pii: e19671 2017 10.7554/eLife.19671 28094001 PMC5241115 · DOI · Paper page
  72. [77]Egawa Y Saigo C Kito Y Moriki T Takeuchi T Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma PLoS One 13 e0198940 2018 10.1371/journal.pone.0198940 29879220 PMC5991736 · DOI
  73. [78]Liu L Han C Yu H Zhu W Cui H Zheng L Zhang C Yue L Chloroquine inhibits cell growth in human A549 lung cancer cells by blocking autophagy and inducing mitochondri-almediated apoptosis Oncol Rep 39 2807 2816 2018 29658606
  74. [80]King MA Ganley IG Flemington V Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells Oncogene 35 4518 4528 2016 10.1038/onc.2015.511 26853465 PMC5000518 · DOI
  75. [81]Weyerhauser P Kantelhardt SR Kim EL Re-purposing chloroquine for glioblastoma: Potential merits and confounding variables Front Oncol 8 335 2018 10.3389/fonc.2018.00335 30211116 PMC6120043 · DOI
  76. [82]Kim J Yip ML Shen X Li H Hsin LY Labarge S Heinrich EL Lee W Lu J Vaidehi N Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells PLoS One 7 e31004 2012 10.1371/journal.pone.0031004 22319600 PMC3272047 · DOI
  77. [83]Mereddy G Ronayne CJ Repurposing antimalarial drug mefloquine for cancer Treatment Transl Med (Sunnyvale) 8 99 2018 10.4172/2161-1025.1000199 · DOI
  78. [84]Ahmed U Jones H Adams CE Chlorpromazine for psychosis-induced aggression or agitation Schizophr Bull 37 890 891 2011 10.1093/schbul/sbr096 21860034 PMC3160230 · DOI
  79. [85]Heinrich JC Donakonda S Haupt VJ Lennig P Zhang Y Schroeder M New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells Oncotarget 7 68156 68169 2016 10.18632/oncotarget.11905 27626687 PMC5356546 · DOI
  80. [86]Gil-Ad I Shtaif B Levkovitz Y Dayag M Zeldich E Weizman A Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: Clinical relevance and possible application for brain-derived tumors J Mol Neurosci 22 189 198 2004 10.1385/JMN:22:3:189 14997012 · DOI
  81. [87]Shin SY Kim CG Kim SH Kim YS Lim Y Lee YH Chlorpromazine activates p21Waf1/Cip1 gene transcription via early growth response-1 (Egr-1) in C6 glioma cells Exp Mol Med 42 395 405 2010 10.3858/emm.2010.42.5.041 20368687 PMC2877254 · DOI
  82. [88]Cuomo F Altucci L Cobellis G Autophagy function and dysfunction: Potential drugs as Anti-cancer therapy Cancers (Basel) 11 pii: E1465 2019 10.3390/cancers11101465 PMC6826381 31569540 · DOI
  83. [89]Shin SY Lee KS Choi YK Lim HJ Lee HG Lim Y Lee YH The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells Carcinogenesis 34 2080 2089 2013 10.1093/carcin/bgt169 23689352 · DOI
  84. [91]Michalak K Wesolowska O Motohashi N Molnar J Hendrich AB Interactions of phenothiazines with lipid bilayer and their role in multidrug resistance reversal Curr Drug Targets 7 1095 1105 2006 10.2174/138945006778226570 17017888 · DOI
  85. [92]Zhelev Z Ohba H Bakalova R Hadjimitova V Ishikawa M Shinohara Y Baba Y Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia Cancer Chemother Pharmacol 53 267 275 2004 10.1007/s00280-003-0738-1 14663628 · DOI
  86. [93]Yde CW Clausen MP Bennetzen MV Lykkesfeldt AE Mouritsen OG Guerra B The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells Anticancer Drugs 20 723 735 2009 10.1097/CAD.0b013e32832ec041 19584708 · DOI
  87. [94]Lee WY Lee WT Cheng CH Chen KC Chou CM Chung CH Sun MS Cheng HW Ho MN Lin CW Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1 Oncotarget 6 27580 27595 2015 26363315 PMC4695010
  88. [95]Chen MH Yang WL Lin KT Liu CH Liu YW Huang KW Chang PM Lai JM Hsu CN Chao KM Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma PLoS One 6 e27186 2011 10.1371/journal.pone.0027186 22087264 PMC3210146 · DOI
  89. [96]Lee MS Johansen L Zhang Y Wilson A Keegan M Avery W Elliott P Borisy AA Keith CT The novel combination of chlorpromazine and pentamidine exerts synergistic antipro-liferative effects through dual mitotic action Cancer Res 67 11359 11367 2007 10.1158/0008-5472.CAN-07-2235 18056463 · DOI
  90. [97]Cottingham C Percival S Birky T Wang Q Tricyclic antidepressants exhibit variable pharmacological profiles at the alpha(2A) adrenergic receptor Biochem Biophys Res Commun 451 461 466 2014 10.1016/j.bbrc.2014.08.024 25128275 PMC4150853 · DOI
  91. [98]Benkelfat C Murphy DL Zohar J Hill JL Grover G Insel TR Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action Arch Gen Psychiatry 46 23 28 1989 10.1001/archpsyc.1989.01810010025004 2910220 · DOI
  92. [99]Levkovitz Y Arnest G Mendlovic S Treves I Fennig S The effect of Ondansetron on memory in schizophrenic patients Brain Res Bull 65 291 295 2005 10.1016/j.brainresbull.2003.09.022 15811593 · DOI
  93. [100]Rundle-Thiele D Head R Cosgrove L Martin JH Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma Br J Clin Pharmacol 81 199 209 2016 10.1111/bcp.12785 26374633 PMC4833171 · DOI
  94. [101]Higgins SC Pilkington GJ The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma Anticancer Res 30 391 397 2010 20332444
  95. [102]Tzadok S Beery E Israeli M Uziel O Lahav M Fenig E Gil-Ad I Weizman A Nordenberg J In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells Int J Oncol 37 1043 1051 2010 20811727
  96. [103]Xia Z Bergstrand A DePierre JW Nässberger L The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation J Biochem Mol Toxicol 13 338 347 1999 10.1002/(SICI)1099-0461(1999)13:6<338::AID-JBT8>3.0.CO;2-7 10487422 · DOI
  97. [104]Daley E Wilkie D Loesch A Hargreaves IP Kendall DA Pilkington GJ Bates TE Chlorimipramine: A novel anticancer agent with a mitochondrial target Biochem Biophys Res Commun 328 623 632 2005 10.1016/j.bbrc.2005.01.028 15694394 · DOI
  98. [105]Bilir A Erguven M Oktem G Ozdemir A Uslu A Aktas E Bonavida B Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma Int J Oncol 32 829 839 2008 18360710
  99. [106]Merry S Hamilton TG Flanigan P Freshney RI Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31 34 1991 10.1016/0277-5379(91)90054-H 1826436 · DOI
  100. [107]Lu HA Diabetes Insipidus Adv Exp Med Biol 969 213 225 2017 10.1007/978-94-024-1057-0_14 28258576 · DOI
  101. [108]Agerso H Seiding Larsen L Riis A Lövgren U Karlsson MO Senderovitz T Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients Br J Clin Pharmacol 58 352 358 2004 10.1111/j.1365-2125.2004.02175.x 15373927 PMC1884604 · DOI
  102. [109]Deen PM van Balkom BW Kamsteeg EJ Routing of the aquaporin-2 water channel in health and disease Eur J Cell Biol 79 523 530 2000 10.1078/0171-9335-00075 11001488 · DOI
  103. [110]Hamilton KL Devor DC Basolateral membrane K+ channels in renal epithelial cells Am J Physiol Renal Physiol 302 F1069 F1081 2012 10.1152/ajprenal.00646.2011 22338089 PMC3362169 · DOI
  104. [111]Mannucci PM Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years Blood 90 2515 2521 1997 10.1182/blood.V90.7.2515 9326215 · DOI
  105. [112]Andersson KE Van Kerrebroeck P Pharmacotherapy for Nocturia Curr Urol Rep 19 8 2018 10.1007/s11934-018-0750-y 29427214 PMC5807446 · DOI
  106. [113]North WG Gene regulation of vasopressin and vasopressin receptors in cancer Exp Physiol 85 Spec No: 27S-40S 2000 10.1111/j.1469-445X.2000.tb00005.x 10795904 · DOI
  107. [114]Alonso DF Skilton G Farias EF Bal de Kier Joffe E Gomez DE Antimetastatic effect of desmopressin in a mouse mammary tumor model Breast Cancer Res Treat 57 271 275 1999 10.1023/A:1006291607871 10617303 · DOI
  108. [115]Giron S Tejera AM Ripoll GV Gomez DE Alonso DF Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation J Surg Oncol 81 38 44 2002 10.1002/jso.10141 12210026 · DOI
  109. [116]Ripoll GV Garona J Hermo GA Gomez DE Alonso DF Effects of the synthetic vasopressin analog desmopressin in a mouse model of colon cancer Anticancer Res 30 5049 5054 2010 21187489
  110. [117]Ripoll GV Farina HG Yoshiji H Gomez DE Alonso DF Desmopressin reduces melanoma lung metastasis in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1 In Vivo 20 881 885 2006 17203783
  111. [118]Hermo GA Torres P Ripoll GV Scursoni AM Gomez DE Alonso DF Gobello C Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study Vet J 178 103 108 2008 10.1016/j.tvjl.2007.06.015 17719812 · DOI
  112. [119]Ripoll GV Garona J Pifano M Farina HG Gomez DE Alonso DF Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model Breast Cancer Res Treat 142 9 18 2013 10.1007/s10549-013-2724-6 24122393 PMC3825504 · DOI
  113. [120]Garona J Pifano M Orlando UD Pastrian MB Iannucci NB Ortega HH Podesta EJ Gomez DE Ripoll GV Alonso DF The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models Int J Oncol 46 2335 2345 2015 10.3892/ijo.2015.2952 25846632 PMC4441290 · DOI
  114. [121]Weinberg RS Grecco MO Ferro GS Seigelshifer DJ Perroni NV Terrier FJ Sánchez-Luceros A Maronna E Sánchez-Marull R Frahm I A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients Springerplus 4 428 2015 10.1186/s40064-015-1217-y 26306290 PMC4540720 · DOI
  115. [122]Sasaki H Klotz LH Sugar LM Kiss A Venkateswaran V A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells Biochem Biophys Res Commun 464 848 854 2015 10.1016/j.bbrc.2015.07.050 26182875 · DOI
  116. [123]Bass R Roberto D Wang DZ Cantu FP Mohamadi RM Kelley SO Klotz L Venkateswaran V Combining desmopressin and docetaxel for the treatment of castration-resistant prostate cancer in an orthotopic model Anticancer Res 39 113 118 2019 10.21873/anticanres.13086 30591447 · DOI
  117. [124]Rose A Andre N Rozados VR Mainetti LE Menacho Márquez M Rico MJ Schaiquevich P Villarroel M Gregianin L Graupera JM Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016Rosario, Argentina Ecancermedicalscience 10 672 2016 10.3332/ecancer.2016.672 27610198 PMC5014555 · DOI
  118. [125]Hollman A Drugs for atrial fibrillation. Digoxin comes from Digitalis lanata BMJ 312 912 1996 10.1136/bmj.312.7035.912 8611904 PMC2350584 · DOI
  119. [126]Ravi Kumar A Kurup PA Digoxin and membrane sodium potassium ATPase inhibition in cardiovascular disease Indian Heart J 52 315 318 2000 10976153
  120. [127]Sperelakis N Ohya Y Electrophysiology of vascular smooth muscle Physiology and Pathophysiology of the Heart Springer 773 811 1989 10.1007/978-1-4613-0873-7_38 · DOI
  121. [128]Menger L Vacchelli E Kepp O Eggermont A Tartour E Zitvogel L Kroemer G Galluzzi L Trial watch: Cardiac glycosides and cancer therapy Oncoimmunology 2 e23082 2013 10.4161/onci.23082 23525565 PMC3601180 · DOI
  122. [129]Biggar RJ Wohlfahrt J Oudin A Hjuler T Melbye M Digoxin use and the risk of breast cancer in women J Clin Oncol 29 2165 2170 2011 10.1200/JCO.2010.32.8146 21422417 · DOI
  123. [130]Platz EA Yegnasubramanian S Liu JO Chong CR Shim JS Kenfield SA Stampfer MJ Willett WC Giovannucci E Nelson WG A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment Cancer Discov 1 68 77 2011 10.1158/2159-8274.CD-10-0020 22140654 PMC3227223 · DOI
  124. [131]Lin J Zhan T Duffy D Hoffman-Censits J Kilpatrick D Trabulsi EJ Lallas CD Chervoneva I Limentani K Kennedy B A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA Am J Cancer Ther Pharmacol 2 21 32 2014 25580468 PMC4287984
  125. [132]Biggar RJ Molecular pathways: Digoxin use and estrogen-sensitive cancers-risks and possible therapeutic implications Clin Cancer Res 18 2133 2137 2012 10.1158/1078-0432.CCR-11-1389 22368159 · DOI
  126. [135]Frankel AE Eskiocak U Gill JG Yuan S Ramesh V Froehlich TW Ahn C Morrison SJ Digoxin plus trametinib therapy achieves disease control in BRAF Wild-type metastatic melanoma patients Neoplasia 19 255 260 2017 10.1016/j.neo.2017.01.010 28278423 PMC5342980 · DOI
  127. [136]Xia M Huang R Sakamuru S Alcorta D Cho MH Lee DH Park DM Kelley MJ Sommer J Austin CP Identification of repurposed small molecule drugs for chordoma therapy Cancer Biol Ther 14 638 647 2013 10.4161/cbt.24596 23792643 PMC3742493 · DOI
  128. [137]Heldal AT Skurtveit S Lobmaier PPK Vederhus JK Bramness JG Use of drugs for alcohol use disorder in Norway 2004-16 Tidsskr Nor Laegeforen 138 2018 10.4045/tidsskr.18.0383 30421743 · DOI
  129. [138]Huang J Campian JL Gujar AD Tran DD Lockhart AC DeWees TA Tsien CI Kim AH A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy J Neurooncol 128 259 266 2016 10.1007/s11060-016-2104-2 26966095 · DOI · Paper page
  130. [139]Jiao Y Hannafon BN Ding WQ Disulfiram's anticancer activity: Evidence and mechanisms Anticancer Agents Med Chem 16 1378 1384 2016 10.2174/1871520615666160504095040 27141876 · DOI
  131. [140]Liu P Wang Z Brown S Kannappan V Tawari PE Jiang W Irache JM Tang JZ Armesilla AL Darling JL Liposome encapsulated Disulfiram inhibits NFkB pathway and targets breast cancer stem cells in vitro and in vivo Oncotarget 5 7471 7485 2014 10.18632/oncotarget.2166 25277186 PMC4202137 · DOI
  132. [141]Kona FR Buac D M Burger A Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies Curr Cancer Drug Targets 11 338 346 2011 10.2174/156800911794519798 21247383 · DOI
  133. [142]Kuo CF Luo SF See LC Chou IJ Fang YF Yu KH Increased risk of cancer among gout patients: A nationwide population study Joint Bone Spine 79 375 378 2012 10.1016/j.jbspin.2011.09.011 22088929 · DOI
  134. [143]Triscott J Lee C Hu K Fotovati A Berns R Pambid M Luk M Kast RE Kong E Toyota E Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblas-toma and over-rides resistance to temozolomide Oncotarget 3 1112 1123 2012 10.18632/oncotarget.604 23047041 PMC3717961 · DOI
  135. [144]Cvek B TNF-alpha could be responsible for disulfiram-mediated hepatotoxicity J Hepatol 49 865 866 2008 10.1016/j.jhep.2008.07.001 18752862 · DOI
  136. [145]Ekinci E Rohondia S Khan R Dou QP Repurposing disulfiram as an Anti-cancer agent: Updated review on literature and patents Recent Pat Anticancer Drug Discov 14 113 132 2019 10.2174/1574892814666190514104035 31084595 · DOI
  137. [146]Schott B Londos-Gagliardi D Ries C Huet S Robert J Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines J Cancer Res Clin Oncol 119 527 532 1993 10.1007/BF01686462 8100823 PMC12200566 · DOI
  138. [148]Cong J Wang Y Zhang X Zhang N Liu L Soukup K Michelakos T Hong T DeLeo A Cai L A novel chemo-radiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram Cancer Lett 409 9 19 2017 10.1016/j.canlet.2017.08.028 28864067 · DOI
  139. [149]Triscott J Rose Pambid M Dunn SE Concise review: Bullseye: Targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram Stem Cells 33 1042 1046 2015 10.1002/stem.1956 25588723 · DOI
  140. [150]Verma S Stewart DJ Maroun JA Nair RC A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram Am J Clin Oncol 13 119 124 1990 10.1097/00000421-199004000-00007 2180271 · DOI
  141. [151]Schweizer MT Lin J Blackford A Bardia A King S Armstrong AJ Rudek MA Yegnasubramanian S Carducci MA Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer Prostate Cancer Prostatic Dis 16 357 361 2013 10.1038/pcan.2013.28 23958896 PMC3830644 · DOI
  142. [152]Peyriere H Makinson A Marchandin H Reynes J Doxycycline in the management of sexually transmitted infections J Antimicrobial Chemother 73 553 563 2018 29182717
  143. [153]Polikanov YS Aleksashin NA Beckert B Wilson DN The mechanisms of action of ribosome-targeting peptide antibiotics Front Mol Biosci 5 48 2018 10.3389/fmolb.2018.00048 29868608 PMC5960728 · DOI
  144. [154]Gilbertson-Beadling S Powers EA Stamp-Cole M Scott PS Wallace TL Copeland J Petzold G Mitchell M Ledbetter S Poorman R The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metal-loproteinase-dependent mechanism Cancer Chemother Pharmacol 36 418 424 1995 10.1007/BF00686191 7543375 · DOI
  145. [155]Yamazaki M Akahane T Buck T Yoshiji H Gomez DE Schoeffner DJ Okajima E Harris SR Bunce OR Thorgeirsson SS Thorgeirsson UP Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice Carcinogenesis 25 1735 1746 2004 10.1093/carcin/bgh181 15166086 · DOI
  146. [156]Gomez DE Yoshiji H Kim JC Thorgeirsson UP Ulex euro-paeus I lectin induces activation of matrix-metalloproteinase-2 in endothelial cells Biochem Biophys Res Commun 216 177 182 1995 10.1006/bbrc.1995.2607 7488085 · DOI
  147. [157]Lamb R Ozsvari B Lisanti CL Tanowitz HB Howell A Martinez-Outschoorn UE Sotgia F Lisanti MP Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease Oncotarget 6 4569 4584 2015 10.18632/oncotarget.3174 25625193 PMC4467100 · DOI
  148. [158]Scatena C Roncella M Di Paolo A Aretini P Menicagli M Fanelli G Marini C Mazzanti CM Ghilli M Sotgia F Doxycycline, an inhibitor of mitochondrial biogenesis, effectively reduces cancer stem cells (CSCs) in early breast cancer patients: A clinical pilot study Front Oncol 8 452 2018 10.3389/fonc.2018.00452 30364293 PMC6194352 · DOI
  149. [159]Pulvino M Chen L Oleksyn D Li J Compitello G Rossi R Spence S Balakrishnan V Jordan C Poligone B Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline Oncotarget 6 14796 14813 2015 10.18632/oncotarget.4193 26142707 PMC4558116 · DOI
  150. [160]Son K Fujioka S Iida T Furukawa K Fujita T Yamada H Chiao PJ Yanaga K Doxycycline induces apoptosis in PANC-1 pancreatic cancer cells Anticancer Res 29 3995 4003 2009 19846942
  151. [161]Duivenvoorden WC Popović SV Lhoták S Seidlitz E Hirte HW Tozer RG Singh G Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer Cancer Res 62 1588 1591 2002 11912125
  152. [162]Wan L Dong H Xu H Ma J Zhu Y Lu Y Wang J Zhang T Li T Xie J Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: Prevent seeds from gemmating on soil Oncotarget 6 35157 35172 2015 10.18632/oncotarget.6038 26459390 PMC4742096 · DOI
  153. [163]Qin Y Zhang Q Lee S Zhong WL Liu YR Liu HJ Zhao D Chen S Xiao T Meng J Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells Oncotarget 6 40667 40679 2015 10.18632/oncotarget.5842 26512779 PMC4747360 · DOI
  154. [164]Davis AJ Chen BP Chen DJ DNA-PK: A dynamic enzyme in a versatile DSB repair pathway DNA Repair (Amst) 17 21 29 2014 10.1016/j.dnarep.2014.02.020 24680878 PMC4032623 · DOI
  155. [165]Lamb R Fiorillo M Chadwick A Ozsvari B Reeves KJ Smith DL Clarke RB Howell SJ Cappello AR Martinez-Outschoorn UE Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy Oncotarget 6 14005 14025 2015 10.18632/oncotarget.4159 26087309 PMC4546447 · DOI
  156. [166]Shimomura A Takasaki A Nomura R Hayashi N Senda T Identification of DNA-dependent protein kinase catalytic subunit as a novel interaction partner of lymphocyte enhancer factor 1 Med Mol Morphol 46 14 19 2013 10.1007/s00795-012-0002-z 23325550 · DOI
  157. [167]Alexander-Savino CV Hayden MS Richardson C Zhao J Poligone B Doxycycline is an NF-kB inhibitor that induces apoptotic cell death in malignant T-cells Oncotarget 7 75954 75967 2016 10.18632/oncotarget.12488 27732942 PMC5342790 · DOI
  158. [168]Xu N Wang Q Jiang S Wang Q Hu W Zhou S Zhao L Xie L Chen J Wellstein A Lai EY Fenofibrate improves vascular endothelial function and contractility in diabetic mice Redox Biol 20 87 97 2019 10.1016/j.redox.2018.09.024 30296701 PMC6174921 · DOI
  159. [169]Li T Zhang Q Zhang J Yang G Shao Z Luo J Fan M Ni C Wu Z Hu X Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-kB pathway BMC Cancer 14 96 2014 10.1186/1471-2407-14-96 24529079 PMC4015735 · DOI
  160. [170]Shigeto T Yokoyama Y Xin B Mizunuma H Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer Oncol Rep 18 833 840 2007 17786343
  161. [171]Liu H Zang C Fenner MH Liu D Possinger K Koeffler HP Elstner E Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18 Blood 107 3683 3692 2006 10.1182/blood-2005-05-2103 16403907 · DOI
  162. [172]Zhu Y Dean AE Horikoshi N Heer C Spitz DR Gius D Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy J Clin Invest 128 3682 3691 2018 10.1172/JCI120844 30168803 PMC6118595 · DOI
  163. [173]Jan CI Tsai MH Chiu CF Huang YP Liu CJ Chang NW Fenofibrate suppresses oral tumorigenesis via reprogramming metabolic processes: Potential drug repurposing for oral cancer Int J Biol Sci 12 786 798 2016 10.7150/ijbs.13851 27313493 PMC4910598 · DOI
  164. [174]Luo F Li Y Yuan F Zuo J Hexokinase II promotes the Warburg effect by phosphorylating alpha subunit of pyruvate dehydrogenase Chin J Cancer Res 31 521 532 2019 10.21147/j.issn.1000-9604.2019.03.14 31354221 PMC6613503 · DOI
  165. [176]Pedersen PL Voltage dependent anion channels (VDACs): A brief introduction with a focus on the outer mitochondrial compartment's roles together with hexokinase-2 in the 'Warburg effect' in cancer J Bioenerg Biomembr 40 123 126 2008 10.1007/s10863-008-9165-7 18780167 · DOI
  166. [177]Nielsen MH Pedersen FS Kjems J Molecular strategies to inhibit HIV-1 replication Retrovirology 2 10 2005 10.1186/1742-4690-2-10 15715913 PMC553987 · DOI
  167. [178]Jensen K Bikas A Patel A Kushchayeva Y Costello J McDaniel D Burman K Vasko V Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells Endocr Relat Cancer 24 147 156 2017 10.1530/ERC-16-0568 28137980 · DOI
  168. [179]Wilson JM Fokas E Dutton SJ Patel N Hawkins MA Eccles C Chu KY Durrant L Abraham AG Partridge M ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer Radiother Oncol 119 306 311 2016 10.1016/j.radonc.2016.03.021 27117177 PMC4917892 · DOI
  169. [180]Hoover AC Milhem MM Anderson CM Sun W Smith BJ Hoffman HT Buatti JM Efficacy of nelfinavir as mono-therapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial Head Neck 37 722 726 2015 10.1002/hed.23664 24596143 PMC4285572 · DOI
  170. [181]Goda JS Pachpor T Basu T Chopra S Gota V Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers Indian J Med Res 143 145 159 2016 10.4103/0971-5916.180201 27121513 PMC4859124 · DOI
  171. [182]Jiang W Mikochik PJ Ra JH Lei H Flaherty KT Winkler JD Spitz FR HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest Cancer Res 67 1221 1227 2007 10.1158/0008-5472.CAN-06-3377 17283158 · DOI
  172. [183]Srirangam A Mitra R Wang M Gorski JC Badve S Baldridge L Hamilton J Kishimoto H Hawes J Li L Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer Clin Cancer Res 12 1883 1896 2006 10.1158/1078-0432.CCR-05-1167 16551874 PMC2727652 · DOI
  173. [184]Mahoney E Maddocks K Flynn J Jones J Cole SL Zhang X Byrd JC Johnson AJ Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: A new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies Leuk Lymphoma 54 2685 2692 2013 10.3109/10428194.2013.781168 23469959 PMC3815958 · DOI
  174. [185]Pore N Gupta AK Cerniglia GJ Maity A HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells Neoplasia 8 889 895 2006 10.1593/neo.06535 17132220 PMC1716015 · DOI
  175. [186]Hampson L Kitchener HC Hampson IN Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro Antivir Ther 11 813 825 2006 17310826
  176. [187]Yang Y Ikezoe T Nishioka C Bandobashi K Takeuchi T Adachi Y Kobayashi M Takeuchi S Koeffler HP Taguchi H NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines Br J Cancer 95 1653 1662 2006 10.1038/sj.bjc.6603435 17133272 PMC2360758 · DOI
  177. [188]Pajonk F Himmelsbach J Riess K Sommer A McBride WH The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells Cancer Res 62 5230 5235 2002 12234989
  178. [189]Yang Y Ikezoe T Takeuchi T Adachi Y Ohtsuki Y Takeuchi S Koeffler HP Taguchi H HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling Cancer Sci 96 425 433 2005 10.1111/j.1349-7006.2005.00063.x 16053514 PMC11158579 · DOI
  179. [190]Koltai T Nelfinavir and other protease inhibitors in cancer: Mechanisms involved in anticancer activity F1000Res 4 9 2015 10.12688/f1000research.5827.2 26097685 PMC4457118 · DOI
  180. [191]Bruning A Vogel M Burger P Rahmeh M Gingelmaier A Friese K Lenhard M Burges A Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells Biochem Biophys Res Commun 377 1309 1314 2008 10.1016/j.bbrc.2008.10.167 19000651 · DOI
  181. [192]Gupta V Samuleson CG Su S Chen TC Nelfinavir poten-tiation of imatinib cytotoxicity in meningioma cells via survivin inhibition Neurosurg Focus 23 E9 2007 10.3171/FOC-07/10/E9 17961046 · DOI
  182. [193]Xie L Evangelidis T Xie L Bourne PE Drug discovery using chemical systems biology: Weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir PLoS Comput Biol 7 e1002037 2011 10.1371/journal.pcbi.1002037 21552547 PMC3084228 · DOI
  183. [194]Lenhard JM Croom DK Weiel JE Winegar DA HIV protease inhibitors stimulate hepatic triglyceride synthesis Arterioscler Thromb Vasc Biol 20 2625 2629 2000 10.1161/01.ATV.20.12.2625 11116063 · DOI
  184. [195]McBrayer SK Cheng JC Singhal S Krett NL Rosen ST Shanmugam M Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: Implications for glucose transporter-directed therapy Blood 119 4686 4697 2012 10.1182/blood-2011-09-377846 22452979 PMC3367873 · DOI
  185. [196]Laurent N de Bouard S Guillamo JS Christov C Zini R Jouault H Andre P Lotteau V Peschanski M Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo Mol Cancer Ther 3 129 136 2004 14985453
  186. [197]Kast RE The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir Chin J Cancer 34 161 165 2015 10.1186/s40880-015-0010-1 25963312 PMC4593370 · DOI
  187. [198]Ikezoe T Saito T Bandobashi K Yang Y Koeffler HP Taguchi H HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2 Mol Cancer Ther 3 473 479 2004 15078991
  188. [199]Kast RE Karpel-Massler G Halatsch ME CUSP9* treatment protocol for recurrent glioblastoma: Aprepitant, arte-sunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide Oncotarget 5 8052 8082 2014 10.18632/oncotarget.2408 25211298 PMC4226667 · DOI
  189. [200]Mendez-Lopez M Sutter T Driessen C Besse L HIV protease inhibitors for the treatment of multiple myeloma Clin Adv Hematol Oncol 17 615 623 2019 31851164
  190. [201]Ondieki G Nyagblordzro M Kikete S Liang R Wang L He X Cytochrome P450 and P-Glycoprotein-mediated interactions involving african herbs indicated for common noncommunicable diseases Evid Based Complement Alternat Med 2017 2582463 2017 10.1155/2017/2582463 28250793 PMC5307007 · DOI
  191. [202]Perrotti D Jamieson C Goldman J Skorski T Chronic myeloid leukemia: Mechanisms of blastic transformation J Clin Invest 120 2254 2264 2010 10.1172/JCI41246 20592475 PMC2898591 · DOI
  192. [203]Jabbour E Parikh SA Kantarjian H Cortes J Chronic myeloid leukemia: Mechanisms of resistance and treatment Hematol Oncol Clin North Am 25 981 995 v 2011 10.1016/j.hoc.2011.09.004 22054730 PMC4428141 · DOI · Paper page
  193. [204]Bixby D Talpaz M Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance Hematology Am Soc Hematol Educ Program: 461 476 2009 10.1182/asheducation-2009.1.461 20008232 · DOI
  194. [205]Xu HL Wang ZJ Liang XM Li X Shi Z Zhou N Bao JK In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs Mol Biosyst 10 1524 1537 2014 10.1039/c3mb70577c 24691568 · DOI
  195. [206]Ahluwalia MS Patton C Stevens G Tekautz T Angelov L Vogelbaum MA Weil RJ Chao S Elson P Suh JH Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas J Neurooncol 102 317 321 2011 10.1007/s11060-010-0325-3 20683757 · DOI
  196. [207]Rathbun RC Liedtke MD Antiretroviral drug interactions: Overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management Pharmaceutics 3 745 781 2011 10.3390/pharmaceutics3040745 24309307 PMC3857057 · DOI
  197. [208]Kast RE Ritonavir and disulfiram may be synergistic in lowering active interleukin-18 levels in acute pancreatitis, and thereby hasten recovery JOP 9 350 353 2008 18469453
  198. [209]Piliero PJ Interaction between ritonavir and statins Am J Med 112 510 511 2002 10.1016/S0002-9343(02)01034-3 11959074 · DOI
  199. [210]Maertens JA History of the development of azole derivatives Clin Microbiol Infect 10 Suppl 1 S1 S10 2004 10.1111/j.1470-9465.2004.00841.x 14748798 · DOI
  200. [211]Vanden Bossche H Marichal P Le Jeune L Coene MC Gorrens J Cools W Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans Antimicrob Agents Chemother 37 2101 2105 1993 10.1128/AAC.37.10.2101 8257130 PMC192235 · DOI

200 of 544 shown

Cited by

Sorted by citations

Authors
Armando, R., Mengual G�mez, D., & Gomez, D.
Affiliations
  • National University of Quilmes (AR)
  • Laboratory of Molecular Oncology, Science and Technology Department, National University of Quilmes, Bernal B1876, Argentina
Corresponding author
Gomez, Daniel
ORCID
Venue
International Journal of Oncology
Publisher
Spandidos Publications
Published
2020-01-20
Volume
56
Issue
3
Pages
651-684
ISSN
  • 1019-6439 (ISSN-L)
  • 1791-2423
DOI
10.3892/ijo.2020.4966
PMC
PMC7010222
OpenAlex
W2999529909
Cited by
90
References
16
Citations by year
2026: 3 · 2025: 9 · 2024: 14 · 2023: 14 · 2022: 17 · 2021: 22 · 2020: 9 · 2019: 1 · 2018: 1
FWCI
2.38
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • International Journal of Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • CONICET Digital (CONICET) (submittedVersion, cc-by-nc-nd)
Funders
Consejo Nacional de Investigaciones Científicas y Técnicas
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
drug repurposing, cancer therapy, anticancer mechanism, repurposed drugs, anticancer drug development
MeSH terms
Antineoplastic Agents, Clinical Trials as Topic, Humans, Neoplasms, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review